MRNY ETF Faces Downside Risks Amid Structural Revenue Decline at Moderna

Analysts have maintained a 'Sell' rating on the MRNY ETF, a YieldMax fund tracking Moderna’s stock through an option income strategy, citing heightened downside risks. The bearish outlook stems from overvalued optimism regarding Moderna's (MRNA) product pipeline despite a structural decline in its core revenue base. The ETF employs a 100% covered call strategy, which effectively caps potential upside while offering minimal protection against significant price drops. While the fund provides high income distributions, these payouts may mask the underlying capital erosion caused by MRNA's weakening financial position. Progress in Moderna's oncology pipeline is reportedly already priced into its current elevated valuation, leaving little room for further growth. Consequently, the combination of limited capital protection and a deteriorating fundamental outlook for the underlying asset suggests continued pressure on the ETF.